PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome

Exclusion Criteria

• •1. Intolerance or contraindication to the use of clopidogrel or aspirin.
• •2. Thrombocytopenia as defined by platelet count \< 100,000/mm3.
• •3. Current use or use within the past 3 months of oral anticoagulants, or dipyridamole or thienopyridine (ticlopidine or open-label clopidogrel) or oral glucocorticoids.
• •4. Daily aspirin in excess of 81 mg, or chronic use of non-steroidal anti-inflammatory agents.
• •5. Use of oral hormone replacement therapy or oral contraceptives including transdermal patch.
• •6. History of pathologic bleeding (i.e., peptic ulcer or intracranial hemorrhage).
• •7. History of chronic inflammatory disease or any recent medical event(s) resulting in tissue injury, infection, or inflammation.
• •8. Myocardial infarction, coronary artery bypass graft, or angioplasty within the 6 months prior to Screening.
• •9. Uncontrolled hypertension (systolic blood pressure \>/= 180 mmHg or diastolic blood pressure \>/= 100 mmHg) at Screening.
• •10. History or presence of cancer in the past 2 years, except for successfully resected basal cell carcinoma of the skin.
• •11. Recent history (within the past 12 months) for alcohol or substance abuse.
• •12. Currently taking another investigational study medication or has taken investigational study medication within 30 days prior to Screening Visit.
• •13. Any condition the Investigator believes would interfere with evaluation of the subject, or which could put the subject at undue risk.